Farhad Zangeneh
Endocrinology, Diabetes & Metabolism · Sterling, VANPI 1114936937
Payments from drug & device makers
Across 1,896 payments — averaging $622.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$577K
- Novo Nordisk$282K
- Bayer$107K
- AbbVie$84K
- Boehringer Ingelheim$63K
- Johnson & Johnson$31K
- plus $38K from 18 others
What the payments were for
- Consulting fees$14,8231%
- Speaking & faculty fees$990,77684%
- Travel & lodging$144,62412%
- Food & beverage$30,5233%
- Education$2630%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 997 | $576,850 |
| Novo Nordisk | 326 | $281,626 |
| Bayer | 133 | $107,469 |
| AbbVie | 136 | $83,826 |
| Boehringer Ingelheim | 113 | $62,999 |
| Johnson & Johnson | 33 | $30,524 |
| Esperion Therapeutics, Inc. | 33 | $17,697 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $8,845 |
| Vivus LLC | 7 | $5,194 |
| IBSA Pharma Inc. | 73 | $2,873 |
| Amgen | 6 | $2,692 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Amarin Pharma, Inc. | 4 | $63 |
| Regeneron Healthcare Solutions, Inc. | 1 | $60 |
| Amneal Pharmaceuticals LLC | 3 | $40 |
| Eisai Inc. | 3 | $36 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
| Pfizer | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| GRT US Holding, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,181,028 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 179 | $250,635 |
| MounjaroTirzepatide | 115 | $132,151 |
| JardianceEmpagliflozin | 87 | $114,001 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 67 | $78,451 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 50 | $74,994 |
| TymlosAbaloparatide | 16 | $61,062 |
| RybelsusSemaglutide | 51 | $55,987 |
| TrulicityDulaglutide | 34 | $38,680 |
| KerendiaFinerenone | 22 | $25,039 |
| FarxigaDapagliflozin Propanediol | 25 | $23,773 |
| ProliaDenosumab | 13 | $22,533 |
| SynthroidLevothyroxine Sodium | 170 | $20,882 |
| Jentadueto XrLinagliptin/Metformin Hcl | 20 | $20,230 |
| Xigduo XrDapaglifloz Propaned/Metformin | 17 | $16,390 |
| JanuviaSitagliptin Phosphate | 12 | $12,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $281,626 | $306,622230 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto Xr, Synjardy | $62,999 | $223,070198 claims |
| Lilly USA, LLCMounjaro, Trulicity | $576,850 | $170,831149 claims |
| MerckJanumet Xr, Januvia | $12 | $87,77862 claims |
| BayerKerendia | $107,469 | $25,03922 claims |
| AmgenProlia | $2,692 | $22,53313 claims |
| AbbVieSynthroid | $83,826 | $20,882170 claims |
| Johnson & JohnsonInvokana | $30,524 | $12,72514 claims |
| Esperion Therapeutics, Inc.Nexlizet | $17,697 | $11,80412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Sterling
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- James la RocqueChesapeake$576K
- Samamtha HudsonMidlothian$372K
- Stacey AndersonCharlottesville$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.